Oculis Q2 2026 Results: Cash Runway Reaches the Second Half of 2029

Oculis (Nasdaq: OCS; XICE: OCS) reported Q2 2026 operating income of CHF0.31 million, entirely from grants, compared with CHF0.26 million a year earlier, while basic and diluted loss per share narrowed to CHF0.16 from CHF0.49. Operating losses widened as expenses increased, but warrant-related fair-value gains and favorable currency movements reduced the quarterly net loss. Cash and short-term investments of CHF228.3 million support the company’s clinical programs into the second half of 2029.

Core Financial Results

Oculis’ operating income remains small relative to its clinical-development spending. Q2 operating expenses increased by CHF2.85 million year over year, with most of that increase coming from general and administrative expenses rather than research and development.

Despite the higher operating loss, the net loss narrowed substantially because the finance result swung from a loss to a gain. This distinction is important because the improvement in reported net income did not come from lower operating costs.

Oculis attributed the broader increase in operating costs primarily to personnel-related expenses, including share-based compensation used to support its development programs.

Clinical Pipeline and Portfolio Priorities

Privosegtor becomes the lead development program

Oculis is shifting its focus toward neuro-ophthalmology, with Privosegtor positioned as its lead late-stage candidate. The PIONEER-1 registration program is evaluating the drug as a neuroprotective treatment for optic neuritis in patients both with and without multiple sclerosis.

Site activation is progressing in the United States, Europe, Australia and Canada. Under the Special Protocol Assessment with the FDA, the primary endpoint is the proportion of patients achieving an improvement of at least 15 letters in low-contrast visual acuity after three months. Patients will be followed for as long as 12 months for safety and tolerability.

The FDA’s neurology division also advised that Oculis would not need additional preclinical studies before submitting an investigational new drug application for Privosegtor in acute multiple sclerosis relapses. The company plans to submit that IND in Q4 2026, using the same 3 mg/kg daily dose for five days as in PIONEER-1. Additional details are expected at a company R&D event during the fourth quarter.

Licaminlimab enrollment advances toward a year-end readout

All planned sites for the PREDICT-1 registration trial in dry eye disease have been activated, and more than 45% of patients have been randomized. The trial is expected to enroll approximately 160 patients, about two-thirds of whom will have the specified TNFR1 genotype.

The primary endpoint measures the change through day 29 in total severe ocular discomfort among patients with that genotype. Oculis expects topline results around year-end. The genotype-based design is intended to identify patients more likely to respond, although the company acknowledges that dry-eye symptom measurements are inherently subjective.

OCS-01 is no longer moving toward a DME filing

Following the May announcement of topline results from the DIAMOND studies, Oculis does not currently plan to seek FDA approval for OCS-01 in diabetic macular edema. That decision reinforces the company’s increased dependence on Privosegtor and Licaminlimab as its principal clinical programs.

Finance Gains Narrowed the Net Loss Despite Weaker Operations

The Q2 finance result improved to a CHF13.60 million gain from a CHF4.63 million loss in the prior-year quarter. The main components were a CHF12.10 million fair-value gain on warrant liabilities and a CHF1.22 million foreign-exchange gain. A year earlier, Oculis recorded a CHF0.23 million warrant-related loss and a CHF4.73 million currency loss.

These accounting and currency movements more than offset the wider operating loss, reducing the quarterly net loss to CHF9.97 million. For the first six months of 2026, the net loss was CHF38.82 million, compared with CHF58.59 million a year earlier; the company similarly attributed the year-to-date improvement primarily to warrant revaluation and favorable U.S. dollar movements against the Swiss franc.

Liquidity and Balance Sheet

Cash, cash equivalents and short-term investments totaled CHF228.3 million, or USD282.3 million, on June 30, 2026. That was up about 7.2% from CHF213.0 million, or USD268.7 million, at the end of 2025.

The increase reflected proceeds from common-share sales under the company’s at-the-market offering program, net of operating expenditures. Within the total, cash and cash equivalents fell to CHF61.6 million from CHF81.3 million, while short-term financial assets increased to CHF166.7 million from CHF131.7 million.

Management expects these resources to fund operations into the second half of 2029. The runway gives Oculis time to advance PIONEER-1, complete PREDICT-1 and begin the planned regulatory process for Privosegtor in acute MS relapses, but it is based partly on capital raised through share issuance rather than operating cash generation.

Risks Investors Need to Monitor

• Clinical and regulatory execution: Privosegtor’s PIONEER-1 program is still activating sites, while the planned acute-MS-relapse IND has not yet been submitted. Delays in enrollment, regulatory review or trial execution could affect the development timeline.
• PREDICT-1 endpoint uncertainty: The Licaminlimab trial relies on a genotype-selected population and a symptom-based primary endpoint that Oculis describes as inherently subjective. The year-end results will be important for validating this precision-medicine approach.
• Greater pipeline concentration: The decision not to pursue an OCS-01 filing for diabetic macular edema leaves Privosegtor and Licaminlimab carrying more of the company’s clinical and regulatory value.
• Continued operating losses and financing needs: Operating expenses rose in Q2, and the increase in liquid resources reflected at-the-market share sales. Future development spending could require additional capital despite the projected runway.
• Volatile reported earnings: Warrant revaluations and foreign-exchange movements drove much of the improvement in Q2 net loss. These items can reverse and may obscure changes in underlying operating performance.

Summary

Oculis’ Q2 2026 results showed a wider operating loss but a substantially narrower net loss because of warrant-related and foreign-exchange gains. The company has sufficient reported liquidity to fund operations into the second half of 2029 and is concentrating its portfolio on Privosegtor and Licaminlimab. The next major points to monitor are the planned Q4 2026 Privosegtor IND submission, continued PIONEER-1 execution and the PREDICT-1 topline results expected around year-end.